isatuximab
E852349
CD38-targeting antibody
anticancer drug
biologic medicinal product
immunoglobulin G1
monoclonal antibody
protein-based drug
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
All labels observed (1)
| Label | Occurrences |
|---|---|
| isatuximab canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292091 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: isatuximab Context triple: [CD38, targetOf, isatuximab]
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: isatuximab Target entity description: Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
-
A.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
CD38-targeting antibody
ⓘ
anticancer drug ⓘ biologic medicinal product ⓘ immunoglobulin G1 ⓘ monoclonal antibody ⓘ protein-based drug ⓘ |
| actsOnCellType |
CD38-expressing hematologic tumor cells
ⓘ
malignant plasma cells ⓘ |
| administrationSchedule | repeated intravenous infusions in 28-day cycles ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| ATCCode | L01FX09 ⓘ |
| bindsTo | CD38 antigen on plasma cells ⓘ |
| commonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ infusion-related reaction ⓘ neutropenia ⓘ pneumonia ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| developer | Sanofi ⓘ |
| drugClass |
antineoplastic agent
ⓘ
immunomodulating agent ⓘ monoclonal antibodies against CD38 ⓘ |
| EMAAuthorizationYear | 2020 ⓘ |
| FDAApprovalYear | 2020 ⓘ |
| hasINN | isatuximab ⓘ |
| hasTradeName | Sarclisa ⓘ |
| indication |
multiple myeloma
ⓘ
refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| marketingAuthorizationHolder | Sanofi ⓘ |
| mechanismOfAction |
induces antibody-dependent cellular cytotoxicity
ⓘ
induces antibody-dependent cellular phagocytosis ⓘ induces complement-dependent cytotoxicity ⓘ induces direct apoptosis of tumor cells ⓘ |
| molecularType | recombinant monoclonal antibody ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targetLocation | cell surface of plasma cells ⓘ |
| targets | CD38 ⓘ |
| therapeuticArea |
hematologic malignancies
ⓘ
oncology ⓘ |
| usedWith |
carfilzomib
ⓘ
dexamethasone ⓘ pomalidomide ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: isatuximab Description of subject: Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.